Ibandronate Sodium Injection
Function and Efficacy
This product is a bisphosphonate bone resorption inhibitor, which may mainly produce anti-bone resorption effect by binding to hydroxyapatite in the bone, inhibiting the dissolution and formation of hydroxyapatite.
Ingredients
Active ingredient: Ibandronate sodium.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| Ibandronate sodiumIngredients |
This product is a bisphosphonate bone resorption inhibitor, which may mainly produce anti-bone resorption effect by binding to hydroxyapatite in the bone, inhibiting the dissolution and formation of hydroxyapatite. More |
138844-81-2 | 25 |
Indication
Hypercalcemia due to malignancy with or without bone metastases.
Usage and Dosage
Dilute 1-4 mg of this product in 500-750 ml of 0.9% saline or 5% glucose solution without calcium ions, and slowly drip intravenously for at least 2 hours. In the treatment of hypercalcemia, the blood calcium concentration should be strictly followed. Before treatment, 0.9% saline should be appropriately given for hydration therapy. Patients with moderate and severe hypercalcemia can be given a single dose of 2-4 mg.
Adverse Reactions
A few patients may experience elevated body temperature and sometimes flu-like symptoms, such as fever, chills, and bone and/or muscle pain. Most cases do not require specific treatment, but some cases may also experience gastrointestinal discomfort. Due to reduced renal calcium excretion, this is often accompanied by a decrease in serum phosphate levels (usually without treatment). Serum calcium levels may drop below normal.
Precautions
It is contraindicated for patients who are allergic to this product or other bisphosphonates, patients with severe renal insufficiency (serum creatinine 5mg/dl), children, pregnant women and lactating women.
Special Population Medication
Precautions during pregnancy and lactation: Pregnant and lactating women are prohibited from using.
Drug Interactions
When this product is used together with aminoglycosides, it may cause a prolonged decrease in blood calcium levels and hypomagnesemia, so extreme caution should be exercised. No studies on the interaction between this product and other drugs have been conducted.
Storage
seal.
Packaging Specification
Based on ibandronic acid 2ml:2mg
Manufacturer
Chengdu Easton Bio Pharmaceuticals Co., Ltd.
-
Founded in:
2009-06-01 -
Address:
No. 8, Xiyuan Avenue, Chengdu Hi-tech Zone -
Tax NO.:
91510100689030428K -
Registered Funds:
176.532256 million yuan -
Website:
-
Email: